The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Implications of the tumor immune microenvironment for staging and therapeutics
Open accessAbstract
Characterizing the tumor immune microenvironment enables the identification of new prognostic and predictive biomarkers, the development of novel therapeutic targets and strategies, and the possibility to guide first-line treatment algorithms. Although the driving elements within the tumor microenvironment of individual primary organ sites differ, many of the salient features remain the same. The presence of a robust antitumor milieu characterized by an abundance of CD8+ cytotoxic T-cells, Th1 helper cells, and associated cytokines often indicates a degree of tumor containment by the immune system and can even lead to tumor elimination. Some of these features have been combined into an ‘Immunoscore’, which has been shown to complement the prognostic ability of the current TNM staging for early stage colorectal carcinomas. Features of the immune microenvironment are also potential therapeutic targets, and immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are especially promising. FDA-approved indications for anti-PD-1/PD-L1 are rapidly expanding across numerous tumor types and, in certain cases, are accompanied by companion or complimentary PD-L1 immunohistochemical diagnostics. Pathologists have direct visual access to tumor tissue and in-depth knowledge of the histological variations between and within tumor types and thus are poised to drive forward our understanding of the tumor microenvironment. This review summarizes the key components of the tumor microenvironment, presents an overview of and the challenges with PD-L1 antibodies and assays, and addresses newer candidate biomarkers, such as CD8+ cell density and mutational load. Characteristics of the local immune contexture and current pathology-related practices for specific tumor types are also addressed. In the future, characterization of the host antitumor immune response using multiplexed and multimodality biomarkers may help predict which patients will respond to immune-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Self-citationGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Self-citationPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citationTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Torre, L. A., Siegel, R. L., & Jemal, A. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-24223-1_1 · Cited by 1,903
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Self-citationTowards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Self-citationLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Self-citationIL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Self-citationKaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Self-citationMlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Self-citationLesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001
Self-citationHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 954
Self-citationSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 927
Self-citationPseudoprogression and Immune-Related Response in Solid Tumors
Chiou, V. L., & Burotto, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6870 · Cited by 903
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Self-citationRoh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Self-citationChow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Self-citationQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837
Self-citationCancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 791
Self-citationPD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Self-citationRandomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
Self-citationLyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Self-citationThompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764
Self-citationProgrammed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Self-citationGreen, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Self-citationArmand, P., Shipp, M. A., Ribrag, V., Michot, J.-M., Zinzani, P. L., Kuruvilla, J., Snyder, E. S., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
Bauml, J., Seiwert, T. Y., Pfister, D. G., Worden, F., Liu, S. V., Gilbert, J., Saba, N. F., Weiss, J., Wirth, L., Sukari, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1524 · Cited by 663
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
The immune score as a new possible approach for the classification of cancer
Galon, J., Pagès, F., Marincola, F. M., Thurin, M., Trinchieri, G., Fox, B. A., Gajewski, T. F., & Ascierto, P. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-1 · Cited by 628
Self-citationPD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Chapuy, B., Roemer, M. G. M., Stewart, C., Tan, Y., Abo, R. P., Zhang, L., Dunford, A. J., Meredith, D. M., Thorner, A. R., Jordanova, E. S., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673236 · Cited by 585
Self-citationAngell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574
Self-citationThompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569
Sunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
Self-citationMcDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Self-citationGiraldo, N. A., Becht, E., Pagès, F., Skliris, G., Verkarre, V., Vano, Y., Mejean, A., Saint-Aubert, N., Lacroix, L., Natario, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2926 · Cited by 507
Self-citationNakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473
Nayak, L., Iwamoto, F. M., LaCasce, A., Mukundan, S., Roemer, M. G. M., Chapuy, B., Armand, P., Rodig, S. J., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-01-764209 · Cited by 453
Self-citationSchalper, K. A., Velcheti, V., Carvajal, D., Wimberly, H., Brown, J., Pusztai, L., & Rimm, D. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2702 · Cited by 450
Self-citationInman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438
Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
Schalper, K. A., Brown, J., Carvajal-Hausdorf, D., McLaughlin, J., Velcheti, V., Syrigos, K. N., Herbst, R. S., & Rimm, D. L. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju435 · Cited by 417
Self-citationLoss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M.-C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00407 · Cited by 379
Self-citationLipson, E. J., Vincent, J. G., Loyo, M., Kagohara, L. T., Luber, B. S., Wang, H., Xu, H., Nayar, S. K., Wang, T. S., Sidransky, D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0034 · Cited by 378
Self-citationRemark, R., Alifano, M., Cremer, I., Lupo, A., Dieu-Nosjean, M.-C., Riquet, M., Crozet, L., Ouakrim, H., Goc, J., Cazes, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3847 · Cited by 375
Giraldo, N. A., Becht, E., Vano, Y., Petitprez, F., Lacroix, L., Validire, P., Sanchez-Salas, R., Ingels, A., Oudard, S., Moatti, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2848 · Cited by 375
Self-citationTumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Totpal, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 365
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Scheel, A. H., Dietel, M., Heukamp, L. C., Jöhrens, K., Kirchner, T., Reu, S., Rüschoff, J., Schildhaus, H.-U., Schirmacher, P., Tiemann, M., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.117 · Cited by 347
Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
Self-citationBerghoff, A. S., Fuchs, E., Ricken, G., Mlecnik, B., Bindea, G., Spanberger, T., Hackl, M., Widhalm, G., Dieckmann, K., Prayer, D., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1057388 · Cited by 309
Self-citationRatcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., Al-Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 301
Herr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., & Oettgen, H. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1404 · Cited by 300
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278
Self-citationBoorjian, S. A., Sheinin, Y., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0731 · Cited by 270
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252
Taube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 246
Self-citationDiverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C., Diab, A., Hymes, S. R., Duvic, M., Hwu, W., Wargo, J. A., Torres‐Cabala, C. A., et al. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 232
Westra, W. H., Taube, J. M., Poeta, M. L., Begum, S., Sidransky, D., & Koch, W. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1402 · Cited by 231
Self-citationIn situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Ladoire, S., Mignot, G., Dabakuyo, S., Arnould, L., Apetoh, L., Rébé, C., Coudert, B., Martin, F., Bizollon, M. H., Vanoli, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2866 · Cited by 226
Burugu, S., Asleh-Aburaya, K., & Nielsen, T. O. (2017) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 222
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 212
Self-citationNanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero-Torres, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Gaule, P., Smithy, J. W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V., & Rimm, D. L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3015 · Cited by 201
Self-citationKadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw436 · Cited by 200
Self-citationHistopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186
Shin, S.-J., Jeon, Y. K., Kim, P.-J., Cho, Y. M., Koh, J., Chung, D. H., & Go, H. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4903-7 · Cited by 180
Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
Faraj, S. F., Munari, E., Guner, G., Taube, J., Anders, R., Hicks, J., Meeker, A., Schoenberg, M., Bivalacqua, T., Drake, C., et al. (2015) · Urology · doi:10.1016/j.urology.2014.10.020 · Cited by 178
Self-citationSteidl, C., Telenius, A., Shah, S. P., Farinha, P., Barclay, L., Boyle, M., Connors, J. M., Horsman, D. E., & Gascoyne, R. D. (2010) · Blood · doi:10.1182/blood-2009-12-257345 · Cited by 176
FOXP3 and survival in urinary bladder cancer
Winerdal, M. E., Marits, P., Winerdal, M., Hasan, M., Rosenblatt, R., Tolf, A., Selling, K., Sherif, A., & Winqvist, O. (2011) · BJU International · doi:10.1111/j.1464-410x.2010.10020.x · Cited by 175
Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., Joseph, R. W., Daud, A. I., Conry, R. M., Gaughan, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0309 · Cited by 171
Self-citationReleasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
Baras, A. S., Drake, C., Liu, J.-J., Gandhi, N., Kates, M., Hoque, M. O., Meeker, A., Hahn, N., Taube, J. M., Schoenberg, M. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1134412 · Cited by 164
Self-citationRehman, J. A., Han, G., Carvajal-Hausdorf, D. E., Wasserman, B. E., Pelekanou, V., Mani, N. L., McLaughlin, J., Schalper, K. A., & Rimm, D. L. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.186 · Cited by 163
Self-citationDanilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
Self-citationShi, M., Roemer, M. G. M., Chapuy, B., Liao, X., Sun, H. H., Pinkus, G. S., Shipp, M. A., Freeman, G. J., & Rodig, S. J. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000297 · Cited by 158
Self-citationPD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Sunshine, J. C., Nguyen, P. L., Kaunitz, G. J., Cottrell, T. R., Berry, S., Esandrio, J., Xu, H., Ogurtsova, A., Bleich, K. B., Cornish, T. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1821 · Cited by 158
Self-citationXylinas, E. N., Robinson, B. D., Kluth, L. A., Volkmer, B. G., Hautmann, R. E., Küfer, R., Zerbib, M., Kwon, E. D., Thompson, R. H., Boorjian, S. A., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.023 · Cited by 153
Falchook, G. S., Leidner, R. S., Stankevich, E., Piening, B., Bifulco, C. B., Lowy, I., & Fury, M. G. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0176-3 · Cited by 152
The immune microenvironment of breast ductal carcinoma in situ
Thompson, E. D., Taube, J. M., Elwood, H. R., Sharma, R. B., Meeker, A. K., Warzecha, H. N., Argani, P., Cimino‐Mathews, A., & Emens, L. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.158 · Cited by 151
Self-citationBasal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Lipson, E. J., Lilo, M. T., Ogurtsova, A., Esandrio, J., Xu, H., Brothers, P., Schollenberger, M. D., Sharfman, W. H., & Taube, J. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0228-3 · Cited by 147
Self-citationImmune targeting in breast cancer.
Cimino‐Mathews, A., Foote, J. B., & Emens, L. A. (2015) · PubMed · Cited by 144
Self-citationKim, H. S., Lee, J. Y., Lim, S. H., Park, K., Sun, J., Ko, Y. H., Baek, C., Son, Y., Jeong, H. S., Ahn, Y. C., et al. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.249 · Cited by 136
Lechner, A., Schlößer, H., Rothschild, S. I., Thelen, M., Reuter, S., Zentis, P., Shimabukuro‐Vornhagen, A., Theurich, S., Wennhold, K., Garcia-Marquez, M. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17901 · Cited by 133
Obeid, J. M., Erdag, G., Smolkin, M. E., Deacon, D. H., Patterson, J. W., Chen, L., Bullock, T. N. J., & Slingluff, C. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235107 · Cited by 131
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Lizotte, P. H., Ivanova, E. V., Awad, M. M., Jones, R. E., Keogh, L., Liu, H., Dries, R., Almonte, C. G., Herter-Sprie, G. S., Santos, A. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89014 · Cited by 125
Self-citationMolecular profiling of head and neck squamous cell carcinoma
Feldman, R. A., Gatalica, Z., Knezetic, J. A., Reddy, S. K., Nathan, C. O., Javadi, N., & Teknos, T. N. (2015) · Head & Neck · doi:10.1002/hed.24290 · Cited by 112
Socinski, M. A., Creelan, B., Horn, L., Reck, M., Paz-Ares, L. G., Steins, M. B., Felip, E., van den Heuvel, M. M., Ciuleanu, T., Badin, F. B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw435.39 · Cited by 111
Kondo, T., Nakazawa, H., Ito, F., Hashimoto, Y., Osaka, Y., Futatsuyama, K., Toma, H., & Tanabe, K. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00231.x · Cited by 105
Galon, J., Mlecnik, B., Marliot, F., Ou, F., Bifulco, C. B., Lugli, A., Zlobec, I., Rau, T. T., Hartmann, A., Masucci, G. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3500 · Cited by 86
Self-citationLi, X., Li, M., Lian, Z., Zhu, H., Kong, L., Wang, P., & Yu, J. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0451-8 · Cited by 78
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma
Yanik, E. L., Kaunitz, G. J., Cottrell, T. R., Succaria, F., McMiller, T. L., Ascierto, M. L., Esandrio, J., Xu, H., Ogurtsova, A., Cornish, T. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0115 · Cited by 78
Self-citationLong-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
Allen, E. M. V., Golay, H. G., Liu, Y., Koyama, S., Wong, K. K. W., Taylor-Weiner, A. N., Giannakis, M., Harden, M. V., Rojas‐Rudilla, V., Chevalier, A. A., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0024 · Cited by 69
Self-citationCutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade
Kaunitz, G. J., Loss, M. J., Rizvi, H. A., Ravi, S., Cuda, J. D., Bleich, K. B., Esandrio, J., Sander, I. B., Le, D. T., Diaz, L. A., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000900 · Cited by 66
Self-citationChen, C.-L., Pan, Q., Zhao, J.-J., Wang, Y., Li, Y.-Q., Wang, Q.-J., Pan, K., Weng, D., Jiang, S.-S., Tang, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1176653 · Cited by 60
Figel, A.-M., Brech, D., Prinz, P. U., Lettenmeyer, U. K., Eckl, J., Turqueti‐Neves, A., Mysliwietz, J., Anz, D., Rieth, N., Muenchmeier, N., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.011 · Cited by 53
Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination
Sharma, S. K., & Bagshawe, K. D. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1247802 · Cited by 51
PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation
Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0145 · Cited by 46
Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance
Wang, Y., Zhuang, Q., Zhou, S., Hu, Z., & Lan, R. (2009) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-009-0116-2 · Cited by 42
Cabillic, F., Bouet-Toussaint, F., Toutirais, O., Rioux-Leclercq, N. C., Fergelot, P., Pintière, C. T. D. L., Genetet, N., Patard, J. J., & Quémener, V. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03212.x · Cited by 38
Immunotherapy for head and neck cancer: the future of treatment?
Xie, X., O’Neill, W. Q., & Pan, Q. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315100 · Cited by 30
Divide and Conquer to Treat Lung Cancer
Johnson, B. E. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611003 · Cited by 19
Piha-Paul, S. A., Bennouna, J., Albright, A. V., Nebozhyn, M., McClanahan, T. K., Ayers, M., Lunceford, J. K., & Ott, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.1536 · Cited by 12
Giraldo, N. A., Kaunitz, G. J., Cottrell, T. R., Berry, S., Sunshine, J. C., Nguyen, P. L., Xu, H., Orgutsova, A., Church, C. D., Miller, N. J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-662 · Cited by 7
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Self-citationThe immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Self-citationLu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, J. M., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 607
Self-citation
Metadata
- Authors
- Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., & Cimino-Mathews, A.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 31
- Issue
- 2
- Pages
- 214-234
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2772146395
- Cited by
- 358
- References
- 163
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.